Skip to content

Blockade of Vascular Potassium Channels During Human Endotoxemia

Blockade of Vascular Potassium Channels During Human Endotoxemia

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00185003
Enrollment
36
Registered
2005-09-16
Start date
2003-01-31
Completion date
2005-06-30
Last updated
2008-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endotoxemia

Keywords

Endotoxemia, vascular potassium channels, cytokine, norepinephrine, regional blood flow,, inflammation,, ion channels,, nitric oxide synthase,, pharmacology.

Brief summary

Background: Activation of NO-synthase and vascular potassium (K) channels may play a role in the sepsis-induced attenuated sensitivity to norepinephrine. We examined whether various K channel blockers and NO-synthase inhibition could restore norepinephrine sensitivity during experimental human endotoxemia.

Interventions

DRUGendotoxin
DRUGPotassium channel blockers: TEA, Quinin, Tolbutamide
DRUGL-NMMA

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy volunteers

Exclusion criteria

* drug, alcohol, nicotine abuse

Design outcomes

Primary

MeasureTime frame
Hemodynamics24 hrs after LPS administration
Markers of Inflammation24 hrs after LPS administration
Cytokines24 hrs after LPS administration
Markers of Renal Injury24 hrs after LPS administration
Inducible NO synthase expression24 hrs after LPS administration
NO-metabolites24 hrs after LPS administration
Mediators of Vascular reactivity24 hrs after LPS administration
Sensitivity to norepinephrine24 hrs after LPS administration

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026